PCCA Variant Rs16957301 is a Novel AKI Risk Genotype-specific for Patients Who Receive ICI Treatment: Real-world Evidence from All of Us Cohort

Overview

Journal Eur J Cancer

Specialty Oncology

Date 2024 Nov 13

PMID 39536432

Authors

Yanfei Wang

Chenxi Xiong

Weifeng Yu

Minghao Zhou

Tyler Shugg

Fang-Chi Hsu

Michael T Eadon

Jing Su

Qianqian Song

Affiliations

Soon will be listed here.

Abstract

Introduction: Immune checkpoint inhibitors (ICIs) enhance the immune system's ability to target and destroy cancer cells, but can also trigger immune-related adverse events (irAEs), such as acute kidney injury (ICI-AKI), complicating patient management. Limited knowledge of genetic predispositions to ICI-AKI highlights the need for genomic studies to improve therapeutic strategies.

Objective: To identify genetic predispositions for ICI-AKI using large-scale real-world data.

Methods: A systematic literature search led to 14 candidate variants related to irAEs. We performed a candidate variant association study with these variants using the All of Us cohort. An ICI-treated cohort and a general cohort were established to evaluate ICI-AKI risk. Logistic regression, adjusted for sex, evaluated the impact of each candidate genotype, separately for self-reported and ancestry-estimated race. Kaplan-Meier survival analysis assessed genetic effects on AKI-free survival.

Results: The ICI cohort (n = 414) showed a one-year AKI incidence rate of 23.2 %, significantly higher than the general cohort (6.5 %, n = 213,282). The rs16957301 variant (chr13:100324308, T > C) in the PCCA gene was a significant risk genotype for ICI-AKI among self-reported White (Beta=0.93, CI: 0.32 - 1.54, ORs= 2.53, Bonferroni-corrected P-value=0.047) and ancestry estimated Europeans (Beta = 0.94, CI: 0.31 - 1.57, ORs= 2.56, Bonferroni-corrected P-value=0.044). Self-reported White with the rs16957301 risk genotypes (TC/CC) developed AKI significantly earlier (3.6 months) compared to the reference genotype (TT, 7.0 months, log-rank P = 0.04). Consistent results were found in ancestry-estimated Europeans. This variant did not present significant AKI risks in the general cohort (Beta: -0.008-0.035, FDR: 0.75-0.99).

Conclusion: Our findings suggest that rs16957301 in PCCA may serve as an ICI-AKI risk marker in Caucasians. Further studies are needed to validate this association and explore risks in other populations.

Citing Articles

Deep Learning-Based Automatic Segmentation Combined with Radiomics to Predict Post-TACE Liver Failure in HCC Patients.

Li S, Liu K, Rong C, Zheng X, Cao B, Guo W J Hepatocell Carcinoma. 2024; 11:2471-2480.

PMID: 39712947 PMC: 11663388. DOI: 10.2147/JHC.S499436.

References

Stein C, Burtey S, Mancini J, Pelletier M, Sallee M, Brunet P . Acute kidney injury in patients treated with anti-programmed death receptor-1 for advanced melanoma: a real-life study in a single-centre cohort. Nephrol Dial Transplant. 2020; 36(9):1664-1674. DOI: 10.1093/ndt/gfaa137. View

Johnson D, Nebhan C, Moslehi J, Balko J . Immune-checkpoint inhibitors: long-term implications of toxicity. Nat Rev Clin Oncol. 2022; 19(4):254-267. PMC: 8790946. DOI: 10.1038/s41571-022-00600-w. View

Garcia-Carro C, Bolufer M, Bury R, Castaneda Z, Munoz E, Felip E . Acute kidney injury as a risk factor for mortality in oncological patients receiving checkpoint inhibitors. Nephrol Dial Transplant. 2021; 37(5):887-894. DOI: 10.1093/ndt/gfab034. View

Luo J, Martucci V, Quandt Z, Groha S, Murray M, Lovly C . Immunotherapy-Mediated Thyroid Dysfunction: Genetic Risk and Impact on Outcomes with PD-1 Blockade in Non-Small Cell Lung Cancer. Clin Cancer Res. 2021; 27(18):5131-5140. PMC: 8815444. DOI: 10.1158/1078-0432.CCR-21-0921. View

Zhao Q, Chen Y, Huang W, Zhou H, Zhang W . Drug-microbiota interactions: an emerging priority for precision medicine. Signal Transduct Target Ther. 2023; 8(1):386. PMC: 10560686. DOI: 10.1038/s41392-023-01619-w. View

Sprangers B, Leaf D, Porta C, Soler M, Perazella M . Diagnosis and management of immune checkpoint inhibitor-associated acute kidney injury. Nat Rev Nephrol. 2022; 18(12):794-805. DOI: 10.1038/s41581-022-00630-8. View

Le N, Tran T, Du Toit C, Gill D, Padmanabhan S . Establishing plausibility of cardiovascular adverse effects of immunotherapies using Mendelian randomisation. Front Cardiovasc Med. 2023; 10:1116799. PMC: 10235787. DOI: 10.3389/fcvm.2023.1116799. View

Wei C, Lee M, Chen Y . Pharmacogenomics of adverse drug reactions: implementing personalized medicine. Hum Mol Genet. 2012; 21(R1):R58-65. DOI: 10.1093/hmg/dds341. View

Zhou P, Liu B, Shen N, Fan X, Lu S, Kong Z . Acute kidney injury in patients treated with immune checkpoint inhibitors: a single-center retrospective study. Ren Fail. 2024; 46(1):2326186. PMC: 10930152. DOI: 10.1080/0886022X.2024.2326186. View

10.

Grangeon M, Tomasini P, Chaleat S, Jeanson A, Souquet-Bressand M, Khobta N . Association Between Immune-related Adverse Events and Efficacy of Immune Checkpoint Inhibitors in Non-small-cell Lung Cancer. Clin Lung Cancer. 2018; 20(3):201-207. DOI: 10.1016/j.cllc.2018.10.002. View

11.

Cuschieri S . The STROBE guidelines. Saudi J Anaesth. 2019; 13(Suppl 1):S31-S34. PMC: 6398292. DOI: 10.4103/sja.SJA_543_18. View

12.

Tan S, Day D, Nicholls S, Segelov E . Immune Checkpoint Inhibitor Therapy in Oncology: Current Uses and Future Directions: State-of-the-Art Review. JACC CardioOncol. 2023; 4(5):579-597. PMC: 9830229. DOI: 10.1016/j.jaccao.2022.09.004. View

13.

Das S, Ciombor K, Haraldsdottir S, Pumpalova Y, Sahin I, Pineda G . Immune-Related Adverse Events and Immune Checkpoint Inhibitor Efficacy in Patients with Gastrointestinal Cancer with Food and Drug Administration-Approved Indications for Immunotherapy. Oncologist. 2020; 25(8):669-679. PMC: 7418359. DOI: 10.1634/theoncologist.2019-0637. View

14.

Jing Y, Chen X, Li K, Liu Y, Zhang Z, Chen Y . Association of antibiotic treatment with immune-related adverse events in patients with cancer receiving immunotherapy. J Immunother Cancer. 2022; 10(1). PMC: 8772460. DOI: 10.1136/jitc-2021-003779. View

15.

Naranbhai V, Viard M, Dean M, Groha S, Braun D, Labaki C . HLA-A*03 and response to immune checkpoint blockade in cancer: an epidemiological biomarker study. Lancet Oncol. 2021; 23(1):172-184. PMC: 8742225. DOI: 10.1016/S1470-2045(21)00582-9. View

16.

Khan Z, Hammer C, Carroll J, Di Nucci F, Acosta S, Maiya V . Genetic variation associated with thyroid autoimmunity shapes the systemic immune response to PD-1 checkpoint blockade. Nat Commun. 2021; 12(1):3355. PMC: 8184890. DOI: 10.1038/s41467-021-23661-4. View

17.

Meraz-Munoz A, Amir E, Ng P, Avila-Casado C, Ragobar C, Chan C . Acute kidney injury associated with immune checkpoint inhibitor therapy: incidence, risk factors and outcomes. J Immunother Cancer. 2020; 8(1). PMC: 7326260. DOI: 10.1136/jitc-2019-000467. View

18.

Kan W, Chen Y, Wu V, Shiao C . Vancomycin-Associated Acute Kidney Injury: A Narrative Review from Pathophysiology to Clinical Application. Int J Mol Sci. 2022; 23(4). PMC: 8877514. DOI: 10.3390/ijms23042052. View

19.

Manohar S, Kompotiatis P, Thongprayoon C, Cheungpasitporn W, Herrmann J, Herrmann S . Programmed cell death protein 1 inhibitor treatment is associated with acute kidney injury and hypocalcemia: meta-analysis. Nephrol Dial Transplant. 2018; 34(1):108-117. DOI: 10.1093/ndt/gfy105. View

20.

Gupta S, Short S, Sise M, Prosek J, Madhavan S, Soler M . Acute kidney injury in patients treated with immune checkpoint inhibitors. J Immunother Cancer. 2021; 9(10). PMC: 8496384. DOI: 10.1136/jitc-2021-003467. View